BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Financials Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Equities
603392
CNE100004090
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.28 CNY | -0.32% |
|
+0.03% | -9.12% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 87,383 | 1,34,459 | 1,14,799 | 95,280 | 86,593 | - | - |
| Enterprise Value (EV) 1 | 87,383 | 1,34,459 | 1,14,799 | 91,759 | 81,324 | 81,340 | 79,930 |
| P/E ratio | 124 x | 66.5 x | 23.9 x | 75.9 x | 38.7 x | 28.3 x | 22.1 x |
| Yield | - | 0.09% | 0.79% | 0.43% | 0.22% | 0.28% | 0.38% |
| Capitalization / Revenue | 37.1 x | 23.4 x | 10.3 x | 17.3 x | 17.9 x | 12 x | 6 x |
| EV / Revenue | 37.1 x | 23.4 x | 10.3 x | 16.7 x | 16.8 x | 11.3 x | 5.54 x |
| EV / EBITDA | 101 x | 55.3 x | 20 x | 55.9 x | 40.1 x | 24.8 x | 11.3 x |
| EV / FCF | 1,08,54,46,252 x | 20,93,23,356 x | 3,58,34,780 x | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | - | - | - | - |
| Price to Book | 34.2 x | 30.1 x | 9.3 x | 7.5 x | 6.23 x | 4.96 x | 3.8 x |
| Nbr of stocks (in thousands) | 12,32,291 | 12,32,291 | 12,68,499 | 12,68,207 | 12,68,207 | - | - |
| Reference price 2 | 70.91 | 109.1 | 90.50 | 75.13 | 68.28 | 68.28 | 68.28 |
| Announcement Date | 04/03/21 | 14/02/22 | 19/01/23 | 28/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,354 | 5,750 | 11,185 | 5,511 | 4,844 | 7,226 | 14,431 |
| EBITDA 1 | 861.7 | 2,430 | 5,739 | 1,641 | 2,026 | 3,274 | 7,099 |
| EBIT 1 | 775.2 | 2,328 | 5,596 | 1,401 | 1,833 | 4,216 | 6,438 |
| Operating Margin | 32.93% | 40.49% | 50.03% | 25.43% | 37.84% | 58.35% | 44.61% |
| Earnings before Tax (EBT) 1 | 764.5 | 2,324 | 5,583 | 1,393 | 1,642 | 2,785 | 6,488 |
| Net income 1 | 677 | 2,021 | 4,736 | 1,248 | 2,553 | 3,466 | 5,552 |
| Net margin | 28.76% | 35.15% | 42.34% | 22.64% | 52.69% | 47.96% | 38.48% |
| EPS 2 | 0.5700 | 1.640 | 3.793 | 0.9900 | 1.765 | 2.415 | 3.094 |
| Free Cash Flow | 80.5 | 642.4 | 3,204 | - | - | - | - |
| FCF margin | 3.42% | 11.17% | 28.64% | - | - | - | - |
| FCF Conversion (EBITDA) | 9.34% | 26.44% | 55.82% | - | - | - | - |
| FCF Conversion (Net income) | 11.89% | 31.78% | 67.65% | - | - | - | - |
| Dividend per Share 2 | - | 0.0985 | 0.7143 | 0.3200 | 0.1474 | 0.1881 | 0.2627 |
| Announcement Date | 04/03/21 | 14/02/22 | 19/01/23 | 28/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,277 | 805.3 | 541.9 | 1,115 | 1,115 | 1,204 | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | 425 | -42.27 | -603.5 | 460.2 | 458.2 | 547.4 | - | - |
| Operating Margin | 33.28% | -5.25% | -111.36% | 41.29% | 41.11% | 45.47% | - | - |
| Earnings before Tax (EBT) 1 | 501.2 | 68.11 | -609.4 | 472.7 | 470.7 | 559.9 | - | - |
| Net income 1 | 457.4 | 106 | -560.7 | 404.9 | 402.9 | 492 | - | - |
| Net margin | 35.82% | 13.16% | -103.47% | 36.32% | 36.14% | 40.87% | - | - |
| EPS 2 | 0.3600 | 0.0900 | -0.4400 | 0.3192 | 0.3177 | 0.3880 | - | - |
| Dividend per Share 2 | - | - | - | 0.0191 | 0.0191 | 0.0191 | 0.0432 | 0.0432 |
| Announcement Date | 24/08/23 | 27/10/23 | 28/03/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 3,521 | 5,270 | 5,253 | 6,663 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | 80.5 | 642 | 3,204 | - | - | - | - |
| ROE (net income / shareholders' equity) | 35.7% | 54% | 56.2% | 9.97% | 10.6% | 23.3% | 27.6% |
| ROA (Net income/ Total Assets) | 23.9% | - | 40.7% | 7.81% | - | - | - |
| Assets 1 | 2,834 | - | 11,638 | 15,972 | - | - | - |
| Book Value Per Share 2 | 2.070 | 3.620 | 9.730 | 10.00 | 11.00 | 13.80 | 18.00 |
| Cash Flow per Share | 0.3800 | 1.360 | 3.260 | 1.210 | - | - | - |
| Capex 1 | 388 | 1,040 | 929 | 1,159 | 446 | 853 | 1,299 |
| Capex / Sales | 16.47% | 18.08% | 8.31% | 21.03% | 9.2% | 11.81% | 9% |
| Announcement Date | 04/03/21 | 14/02/22 | 19/01/23 | 28/03/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
68.28
CNY
Average target price
70.4
CNY
Spread / Average Target
+3.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.12% | 11.97B | |
| -3.79% | 88.14B | |
| +1.45% | 40.51B | |
| -15.94% | 31.67B | |
| +52.66% | 24.62B | |
| -14.50% | 15.65B | |
| -14.38% | 12.07B | |
| -42.56% | 11.61B | |
| +4.87% | 8.81B | |
| -4.33% | 8.5B |
- Stock Market
- Equities
- 603392 Stock
- Financials Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
